Pyridine-3-carboxylate compounds as CAV1.2 activators
AssigneeNovartis AG
InventorsSimon Krautwald, Jianliang Lu, James Anthony Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
Claims17
A compound according to formula (I) or a pharmaceutically acceptable salt thereof
- wherein:
- R1 is selected from C1-6 alkyl and C1-6 haloalkyl;
- R2 is selected from H and halo;
- and
- R3 is selected from C1-6 alkyl and C3-8 cycloalkyl, each of which is optionally substituted with one to three halo.
A compound according to formula (I) or a pharmaceutically acceptable salt thereof
- wherein:
- R1 is selected from CH3, CF3, CHF2 and CH2F;
- R2 is selected from H and F;
- and
- R3 is selected from C1-4 alkyl, cyclopropyl and cyclobutyl each of which is optionally substituted with one to three F.
Dependencies are inferred from the claim text.